A recent study by Triton Market Research titled ‘Global Immunosuppressant Drugs Market,’ covers the Global Analysis and Forecast for 2019-2028 by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), by Drug Class (Monoclonal Antibodies, Corticosteroids, mTOR Inhibitors, Calcineurin Inhibitors, Others), by End-user (Organ Transplantation, Autoimmune Disorders, Others), and by Geographical Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa).
Immunosuppressant drugs are those that inhibit the response of the immune system. They are given to organ transplant patients so that their body does not reject the transplanted organ. These are also used to treat certain autoimmune disorders, such as psoriasis, lupus, and rheumatoid arthritis.
Request Free Sample of the Global Immunosuppressant Drugs Market Report @ https://www.tritonmarketresearch.com/reports/immunosuppressant-drugs-market#request-free-sample
The report on the global immunosuppressant drugs market indicates that this industry will generate revenues worth $14.18 billion by 2028, growing at a CAGR of 4.00% in the forecasting years from 2019 to 2028.
Several people battling genetic conditions, such as PKD, heart defect, and cystic fibrosis, among others, are in dire need of an organ transplant. It is crucial for these patients’ bodies to accept the new organ post the surgical procedure. Immunosuppressive drugs are given to them so that their bodies accept the transplanted organ. Thus, owing to the growing demand for organ transplantation procedures, there is a surge in the demand for immunosuppressant drugs. This is primarily driving the growth of the studied market.
On the other hand, certain side-effects, such as leukopenia & thrombocytopenia, hyperglycemia, hypertension acute & chronic nephrotoxicity, and osteoporosis, have been observed in people who have been given these drugs. This is a serious cause of concern, which is hampering the growth of the immunosuppressant drugs market.
The market for immunosuppressant drugs is primarily classified into distribution channel, drug class, and end-user. According to distribution channel, it is divided into retail pharmacies, hospital pharmacies, and online pharmacies. Whereas, according to drug class, it is segmented into monoclonal antibodies, corticosteroids, mTOR inhibitors, calcineurin inhibitors, and others. On the basis of end-user, it is classified into organ transplantation, autoimmune disorders, and others.
North America is predicted to become the largest market for immunosuppressant drugs, globally, over the forecasting years. There has been a rise in the number of kidney donors in the region, over the years. Kidney transplants account for approx. 60% of the total number of organ transplant procedures. The number of living kidney donors, in particular, has been on the rise.
In addition, Nova Scotia, in Canada, is the first jurisdiction in the entire North American region to have introduced an automatic organ donation program. This is considered as presumed consent, unless the residents opt out of it. Thus, the government has also been taking various initiatives to promote organ donation. These factors are fuelling the growth of the regional market.
GlaxoSmithKline plc, Novartis AG, Astellas Pharma Inc, Abbvie Inc, F Hoffmann-La Roche Ltd, Cipla Ltd, Intas Pharmaceuticals Ltd (Accord Healthcare), Mylan NV, Pfizer Inc, Bristol-Myers Squibb Company, Janssen Pharmaceuticals Inc (Johnson & Johnson Services Inc), Allergan (acquired by Abbvie Inc), Veloxis Pharmaceuticals Inc, Sanofi, and Dr Reddys Laboratories Ltd are the noteworthy names in this market.
Purchase this Report @ https://www.tritonmarketresearch.com/reports/immunosuppressant-drugs-market#purchase-option
Question & Answer: Immunosuppressant Drugs Market
Question 1: What is primarily driving the growth of the immunosuppressant drugs market?
Answer: Several people battling genetic conditions, such as PKD, heart defect, and cystic fibrosis, among others, are in dire need of an organ transplant. It is crucial for these patients’ bodies to accept the new organ post the surgical procedure.
Immunosuppressive drugs are given to them so that their bodies accept the transplanted organ. Thus, owing to the growing demand for organ transplantation procedures, there is a surge in the demand for immunosuppressant drugs. This is primarily driving the growth of the immunosuppressant drugs market.
Question 2: What is hampering the growth of the immunosuppressant drugs market?
Answer: Certain side-effects, such as leukopenia & thrombocytopenia, hyperglycemia, hypertension acute & chronic nephrotoxicity, and osteoporosis, have been observed in people who have been given immunosuppressant drugs. This is a serious cause of concern, which is hampering the growth of the immunosuppressant drugs market.
Question 3: How is North America influencing the growth of the immunosuppressant drugs market?
Answer: North America is predicted to become the largest market for immunosuppressant drugs, globally, over the forecasting years. There has been a rise in the number of kidney donors in the region, over the years. Kidney transplants account for approx. 60% of the total number of organ transplant procedures. The number of living kidney donors, in particular, has been on the rise.
In addition, Nova Scotia, in Canada, is the first jurisdiction in the entire North American region to have introduced an automatic organ donation program. This is considered as presumed consent, unless the residents opt out of it. Thus, the government has also been taking various initiatives to promote organ donation. These factors are fuelling the growth of the regional market.
Question 4: Which are some of the noteworthy names in the immunosuppressant drugs market?
Answer: GlaxoSmithKline plc, Novartis AG, Astellas Pharma Inc, Abbvie Inc, F Hoffmann-La Roche Ltd, Cipla Ltd, Intas Pharmaceuticals Ltd (Accord Healthcare), Mylan NV, Pfizer Inc, Bristol-Myers Squibb Company, Janssen Pharmaceuticals Inc (Johnson & Johnson Services Inc), Allergan (acquired by Abbvie Inc), Veloxis Pharmaceuticals Inc, Sanofi, and Dr Reddys Laboratories Ltd are the noteworthy names in this market.
Related Report:
Global Hyperphosphatemia Market
The global hyperphosphatemia drugs market is expected to exhibit 16.61% of CAGR in the projected years from 2019 to 2027. It will generate a revenue of $11.48 billion by 2027.
Hypertension and diabetes are the main factors causing renal failure. Cases of kidney failure due to high blood pressure increased by 7.7% from the period of 2010 to 2015. Also, in 2016, the total kidney failure cases due to diabetes accounted for 44% of the total number of CKD cases, states the USRDS. Renal failure results in hyperphosphatemia, and the growing cases of these chronic diseases are, in turn, leading to the increase in cases of this condition. This is driving the growth of the concerned market.
In addition, the Kidney Disease Initiative was started by the National Center for Chronic Disease Prevention and Health Promotion. This move was launched with the aim of improving the quality of life of patients suffering from hyperphosphatemia and kidney diseases, by raising awareness about these diseases. Such programs helping to increase public cognizance are fuelling the growth of the global hyperphosphatemia drugs market.
Media Contact
Company Name: Triton Market Research
Contact Person: Matt Dixson
Email: Send Email
Phone: +44 7441 911839
Address:196, wards wharf approach London E16 2EQ
Country: United Kingdom
Website: https://www.tritonmarketresearch.com/